BioXcel Therapeutics, Inc. (BTAI) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

Earnings Reports

• BTAI Q3 2024: R&D Spending Down 74% as BXCL501 Pivotal Trials Advance

  November 14, 2024
• BioXcel Therapeutics (BTAI) Q2 2024: EGALMI Revenue Surges 141% as Home Agitation Trials Advance

  August 06, 2024
• BTAI Q1 2024: Egalmi Revenue Up 182% as Late-Stage Agitation Trials Set Dual Value Path

  May 09, 2024
• BTAI Q4 2023: Cash Runway Shrinks to Mid-2024 as Tranquility and Serenity Prioritized

  March 12, 2024

Browse all companies